Welcome to our dedicated page for Zai Lab news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab stock.
Zai Lab Limited (ZLAB) is a research-based, commercial-stage biopharmaceutical company based in China and the United States, with a focus on oncology, immunology, neuroscience, and infectious disease. The Zai Lab news feed on Stock Titan aggregates company announcements, clinical updates, regulatory milestones, and financial disclosures that the company releases through channels such as Business Wire and SEC filings.
Investors and followers of ZLAB stock can use this page to review news on Zai Lab’s global pipeline, including progress of assets like zocilurtatug pelitecan (zoci), a DLL3-targeted antibody-drug conjugate for extensive-stage small cell lung cancer and other neuroendocrine carcinomas, and ZL-1503, an IL-13/IL-31R bispecific antibody for atopic dermatitis. Updates on other oncology and immunology programs, such as ZL-6201, ZL-1222, and ZL-1311, also appear in company press releases.
The news stream highlights regulatory developments in Greater China, including National Medical Products Administration (NMPA) approvals and National Reimbursement Drug List (NRDL) decisions for products in Zai Lab’s commercial portfolio. Recent examples include announcements about COBENFY for schizophrenia and AUGTYRO for ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors, as well as renewals and coverage decisions for VYVGART, NUZYRA, and ZEJULA.
In addition, this page surfaces Zai Lab’s financial result releases, conference call notices, and participation in healthcare and investor conferences. These items provide context on revenue trends, R&D spending, and the company’s dual-engine strategy combining a China commercial business with a global innovation platform. Bookmark this page to quickly access ZLAB-related news, organized in one place for efficient review of the company’s ongoing clinical, regulatory, and corporate developments.
Zai Lab (NASDAQ: ZLAB) will report first quarter 2026 financial results and provide corporate updates on May 7, 2026 before U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET (8:00 p.m. HKT), with registration required and a replay available on the company website.
Investors can register via the provided webcast or dial-in links; dial-in details are sent after registration.
Zai Lab (NASDAQ: ZLAB) presented preclinical data at IMMUNOLOGY2026 showing that ZL-1503, an IL-13/IL-31Rα bispecific antibody, produced sustained, dose-dependent suppression of itch and Type 2 inflammation for 112 days after a single IV dose in non-human models.
The poster reported improved lung function and reduced airway inflammation at 10 mg/kg, broad TH2 pathway suppression, a favorable nonclinical safety profile, and that Phase 1/1b first-in-human studies began in December 2025 with clinical data expected in 2H 2026.
Zai Lab (NASDAQ: ZLAB) reported that zocilurtatug pelitecan (zoci), a DLL3-targeting ADC, produced a 53.7% confirmed intracranial objective response rate (iORR) in previously treated ES-SCLC with brain metastases; at 1.6 mg/kg confirmed iORR was 62.5% (10/16) including complete responses.
Preliminary epNEC data showed a 38.2% objective response rate. Safety was manageable; grade ≥3 TRAEs occurred in 19.9% overall. Global Phase 3 in second-line-plus SCLC is ongoing and registrational programs are planned in 2026.
Zai Lab and Amgen (NASDAQ: AMGN) announced a global clinical trial collaboration to test Zai Lab’s DLL3-targeting ADC, zocilurtatug pelitecan (zoci), combined with Amgen’s FDA-approved Bispecific T-cell Engager IMDELLTRA® in extensive-stage small cell lung cancer (ES-SCLC).
Amgen will sponsor and lead a global Phase 1b study to evaluate safety and efficacy; Zai Lab will retain full ownership of zoci and supply the study drug. Prior Phase 1/2 data showed high response rates and strong intracranial activity for zoci.
Zai Lab (NASDAQ: ZLAB) will present data on three internally developed oncology candidates at AACR 2026, April 17-22 in San Diego. Posters cover zocilurtatug pelitecan (zoci), a DLL3-targeting ADC with intracranial activity in SCLC, ZL-6201, an LRRC15 ADC for sarcoma, and ZL-1222, a PD-1/IL-12 immunocytokine.
Zai Lab plans three registration-enabling studies for zoci across 2L+, 1L SCLC and extrapulmonary NECs by end of 2026.
Zai Lab (NASDAQ: ZLAB) reported Q4 2025 revenue $127.6M (+17% YoY) and FY2025 revenue $460.2M (+15% YoY). Product revenue growth was led by ZEJULA, XACDURO and NUZYRA. Net loss narrowed to $175.5M for FY2025 from $257.1M in FY2024. Cash and equivalents totaled $789.6M at year-end.
The company accelerated global oncology and immunology programs, highlighting zoci with three registration-enabling studies planned by end-2026, China approval and early 2026 launch plans for KarXT, and pivotal readouts for povetacicept and elegrobart in 2026.
Zai Lab (NASDAQ: ZLAB) will report its fourth quarter and full year 2025 financial results and provide corporate updates on February 26, 2026, before U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET (9:00 p.m. HKT). Participants must register in advance; a replay will be posted on the investor website.
Webcast registration is available via the company’s investor site and provided links; dial-in details are sent after registration.
Zai Lab (NASDAQ: ZLAB) outlined 2026 strategic priorities and pipeline progress at the 44th J.P. Morgan Healthcare Conference on January 13, 2026. Zocilurtatug pelitecan (Zoci) is advancing rapidly with a reported 68% ORR in 2L/3L SCLC at 1.6 mg/kg, a Phase 3 registrational study initiated, and the company expects Zoci to be in three registration-enabling studies across 2L+ SCLC, 1L SCLC and NEC by end-2026. COBENFY received approval in China with a commercial launch planned in 1H 2026. Multiple global programs (ZL-1503, ZL-6201, ZL-1222, ZL-1311) have near-term IND/Phase 1 milestones scheduled for 2026.
Zai Lab (NASDAQ: ZLAB) announced NMPA approval of AUGTYRO (repotrectinib) for adult patients with NTRK‑positive solid tumors who have locally advanced or metastatic disease, or for whom surgery would cause morbidity, and who have progressed after prior therapies or lack satisfactory alternatives. This is AUGTYRO’s second indication in China, and the approval covers both TKI‑naïve and TKI‑pretreated patients. The decision cites data from the pivotal Phase 1/2 TRIDENT‑1 study showing robust, durable efficacy and a manageable safety profile. Zai Lab contributed to TRIDENT‑1 and dosed the first Greater China patient in May 2021. AUGTYRO was earlier approved in China for ROS1‑positive NSCLC in May 2024.
Zai Lab (NASDAQ: ZLAB) announced senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 3:00 p.m. PST / 6:00 p.m. EST. A live webcast will be available on the company's Investor Relations site and an archived replay will be accessible for up to 30 days after the event.
Investors can watch the presentation via webcast at ir.zailaboratory.com/webcasts-presentations.